In the evaluation of total tumor burden in the brain, which was assessed based on whole brain Nluc activity, the combination of anti-PD-L1 and anti-VEGF showed stronger anti-tumor activity than each antibody alone (Fig. 2b). The gene discussed is VEGFA; the disease is neoplasm.